Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-011707

PRESIDENT AND CEO sold 12,000 shares at $16.89 ($202,700)

  • PRESIDENT AND CEO acquired 12,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-04-25 Exercise or conversion : show line 1 in the form 10b5-1 +12,000 $1.12 $13,440 12,000 D
2024-04-25 Sale : show line 2 in the form 10b5-1 −12,000 $16.89 $202,700 0 D
Open-market sales · 12,000 sh · avg $16.89 · $202,700

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-04-25 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −12,000 200,841 D
Loading xslF345X05/form4-04292024_100422.xml…